Peapack-Gladstone Financial Corp’s Atea Pharmaceuticals AVIR Stock Holding History

Peapack-Gladstone Financial Corp’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-15,946	Closed	-$48K	–	696
2023 Q3	$48K	Sell	15,946 -750	-4%	-$2.55K	﹤0.01%	678
2023 Q2	$62K	Hold	16,696	–	–	﹤0.01%	691
2023 Q1	$56K	Hold	16,696	–	–	﹤0.01%	690
2022 Q4	$80K	Sell	16,696 -10,000	-37%	-$50.6K	﹤0.01%	658
2022 Q3	$152K	Hold	26,696	–	–	﹤0.01%	641
2022 Q2	$190K	Sell	26,696 -700	-3%	-$4.78K	﹤0.01%	600
2022 Q1	$198K	Hold	27,396	–	–	﹤0.01%	648
2021 Q4	$245K	Buy	27,396 +20,700	+309%	+$323K	﹤0.01%	597
2021 Q3	$235K	Buy	+6,696	New	+$186K	﹤0.01%	592

Other funds holding AVIR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Peapack-Gladstone Financial Corp's AVIR Position: Q4 2023 in Review

Peapack-Gladstone Financial Corp sold out of Atea Pharmaceuticals (AVIR) in Q4 2023, closing a stake of 15,946 shares — an estimated $48K sold.

Peapack-Gladstone Financial Corp first reported a position in AVIR in Q3 2021 and held it in 9 quarters. The position peaked at $245K in Q4 2021. 108 funds tracked by Wall St. Rank hold AVIR as of Q4 2023.

Peapack-Gladstone Financial Corp reported no remaining Atea Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Peapack-Gladstone Financial Corp sold 15,946 Atea Pharmaceuticals shares in Q4 2023, an estimated $48K.
Peapack-Gladstone Financial Corp first reported a position in Atea Pharmaceuticals in Q3 2021 and held it in 9 quarters.
Peapack-Gladstone Financial Corp's Atea Pharmaceuticals position peaked at $245K in Q4 2021.
108 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2023.

Based on Peapack-Gladstone Financial Corp's 13F filing for Q4 2023, filed 13 Feb 2024.